A treat-to-target study of upadacitinib in atopic dermatitis showed that dosing can be adjusted depending on early patient ...

Upadacitinib demonstrates early and sustained effectiveness up to 1 year in patients with moderate to severe atopic dermatitis in a real-world study.

Researchers examined the risk for serious infection among patients with atopic dermatitis treated with Janus kinase inhibitors vs Th2 cytokine inhibitors.

These are being developed for RA in the first instance, both hitting the mark in phase 3 trials reported last year, but are also potential threats in AD. Upadacitinib is however already in a phase ...

AbbVie’s attempts to diversify beyond Humira have been boosted as its investigational drug upadacitinib has been granted Priority Review by the FDA for moderate to severe rheumatoid arthritis (RA).

The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of AbbVie's upadacitinib (Rinvoq) to treat adults with giant cell arteritis (GCA).